sglt2-inhibitors-neurodegeneration

SGLT2 Inhibitors for Neurodegeneration

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">sglt2-inhibitors-neurodegeneration</th>
</tr>
<tr>
<td class="label">Drug Class</td>
<td>Sodium-Glucose Cotransporter 2 Inhibitors</td>
</tr>
<tr>
<td class="label">Primary Target</td>
<td>SGLT2 transporter (renal)</td>
</tr>
<tr>
<td class="label">Secondary Targets</td>
<td>AMPK, [NLRP3](/entities/nlrp3-inflammasome) inflammasome, mitochondrial function</td>
</tr>
<tr>
<td class="label">Approved Indications</td>
<td>Type 2 Diabetes, Heart Failure, Chronic Kidney Disease</td>
</tr>
<tr>
<td class="label">Neurodegenerative Status</td>
<td>Preclinical/Phase I-II trials</td>
</tr>
<tr>
<td class="label">Route of Administration</td>
<td>Oral</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Brand Names</td>
</tr>
<tr>
<td class="label">Empagliflozin</td>
<td>Jardiance, Glyxambi</td>
</tr>
<tr>
<td class="label">Dapagliflozin</td>
<td>Farxiga, Forxiga</td>
</tr>
<tr>
<td class="label">Canagliflozin</td>
<td>Invokana</td>
</tr>
<tr>
<td class="label">Luseogliflozin</td>
<td>Lusefi</td>
</tr>
<tr>
<td class="label">Sotagliflozin</td>
<td>Zynquista</td>
</tr>
<tr>
<td class="label">Ertugliflozin</td>
<td>Steglatro</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Starting Dose</td>
</tr>
<tr>
<td class="label">Empagliflozin</td>

SGLT2 Inhibitors for Neurodegeneration

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">sglt2-inhibitors-neurodegeneration</th>
</tr>
<tr>
<td class="label">Drug Class</td>
<td>Sodium-Glucose Cotransporter 2 Inhibitors</td>
</tr>
<tr>
<td class="label">Primary Target</td>
<td>SGLT2 transporter (renal)</td>
</tr>
<tr>
<td class="label">Secondary Targets</td>
<td>AMPK, [NLRP3](/entities/nlrp3-inflammasome) inflammasome, mitochondrial function</td>
</tr>
<tr>
<td class="label">Approved Indications</td>
<td>Type 2 Diabetes, Heart Failure, Chronic Kidney Disease</td>
</tr>
<tr>
<td class="label">Neurodegenerative Status</td>
<td>Preclinical/Phase I-II trials</td>
</tr>
<tr>
<td class="label">Route of Administration</td>
<td>Oral</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Brand Names</td>
</tr>
<tr>
<td class="label">Empagliflozin</td>
<td>Jardiance, Glyxambi</td>
</tr>
<tr>
<td class="label">Dapagliflozin</td>
<td>Farxiga, Forxiga</td>
</tr>
<tr>
<td class="label">Canagliflozin</td>
<td>Invokana</td>
</tr>
<tr>
<td class="label">Luseogliflozin</td>
<td>Lusefi</td>
</tr>
<tr>
<td class="label">Sotagliflozin</td>
<td>Zynquista</td>
</tr>
<tr>
<td class="label">Ertugliflozin</td>
<td>Steglatro</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Starting Dose</td>
</tr>
<tr>
<td class="label">Empagliflozin</td>
<td>10 mg daily</td>
</tr>
<tr>
<td class="label">Dapagliflozin</td>
<td>10 mg daily</td>
</tr>
<tr>
<td class="label">Canagliflozin</td>
<td>100 mg daily</td>
</tr>
<tr>
<td class="label">Luseogliflozin</td>
<td>2.5 mg daily</td>
</tr>
<tr>
<td class="label">Adverse Effect</td>
<td>Frequency</td>
</tr>
<tr>
<td class="label">Genital mycotic infections</td>
<td>5-10%</td>
</tr>
<tr>
<td class="label">Urinary tract infections</td>
<td>3-5%</td>
</tr>
<tr>
<td class="label">Increased urination</td>
<td>Common</td>
</tr>
<tr>
<td class="label">Thirst</td>
<td>Common</td>
</tr>
<tr>
<td class="label">Hypotension</td>
<td>2-5%</td>
</tr>
<tr>
<td class="label">Biomarker</td>
<td>Sample</td>
</tr>
<tr>
<td class="label">FDG-PET</td>
<td>Brain imaging</td>
</tr>
<tr>
<td class="label">CSF Aβ42/40</td>
<td>CSF</td>
</tr>
<tr>
<td class="label">CSF total tau</td>
<td>CSF</td>
</tr>
<tr>
<td class="label">CSF p-tau</td>
<td>CSF</td>
</tr>
<tr>
<td class="label">NfL</td>
<td>Blood</td>
</tr>
<tr>
<td class="label">IL-6, TNF-α</td>
<td>Blood/CSF</td>
</tr>
<tr>
<td class="label">BDNF</td>
<td>Blood</td>
</tr>
<tr>
<td class="label">Feature</td>
<td>SGLT2i</td>
</tr>
<tr>
<td class="label">Route</td>
<td>Oral</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Multi-target</td>
</tr>
<tr>
<td class="label">Cost</td>
<td>Low</td>
</tr>
<tr>
<td class="label">Accessibility</td>
<td>High</td>
</tr>
<tr>
<td class="label">Disease modification</td>
<td>Possible</td>
</tr>
</table>

Introduction

Sodium-glucose cotransporter 2 (SGLT2) inhibitors represent a promising class of repurposed antidiabetic drugs that have shown significant neuroprotective potential in neurodegenerative diseases. Originally developed for type 2 diabetes mellitus, these agents have demonstrated benefits far beyond glucose lowering, including reduced neuroinflammation, improved cerebral metabolism, enhanced [autophagy](/entities/autophagy), and protection against oxidative stress[@kousaxidis2020][@sanguanmoo2021]. The growing body of evidence supporting SGLT2 inhibitors in neurodegeneration has generated substantial interest in their potential disease-modifying effects for Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS).

Overview

SGLT2 inhibitors work by blocking the SGLT2 transporter in the renal proximal tubules, resulting in increased urinary glucose excretion and improved glycemic control. However, their neuroprotective effects are mediated through multiple off-target mechanisms that are independent of their renal action["@vallon2020"].

Molecular Mechanism

SGLT2 inhibitors exert neuroprotective effects through several interconnected pathways:

Glucose Metabolism Regulation

The brain relies heavily on glucose as its primary energy source, and cerebral glucose hypometabolism is a hallmark of Alzheimer's disease and other dementias[@cardiovascular2019][@diabetes2020]. SGLT2 inhibitors improve cerebral glucose metabolism through:

• Enhanced cerebral glucose uptake: Improved peripheral insulin sensitivity leads to better glucose availability
• Reduced hippocampal glucose hypometabolism: FDG-PET studies show improved hippocampal glucose uptake
• Enhanced mitochondrial function: Better substrate utilization improves neuronal energy production
• Improved astrocyte-neuron lactate shuttle: Supports neuronal metabolic demands

Neuroinflammation Reduction

Chronic neuroinflammation is a key driver of neurodegeneration. SGLT2 inhibitors reduce neuroinflammation through:

• Decreased microglial activation: Reduced Iba-1 and CD68 staining in animal models
• Reduced pro-inflammatory cytokine production: Lower IL-1β, IL-6, and TNF-α levels
• NLRP3 inflammasome inhibition: Direct inhibition of this key inflammasome complex
• [NF-κB](/entities/nf-kb) pathway modulation: Reduced nuclear translocation of NF-κB

Autophagy Enhancement

Impaired autophagy contributes to protein aggregate accumulation in neurodegenerative diseases. SGLT2 inhibitors:

• Activate AMPK pathway: Primary energy sensor that promotes autophagy
• Improve clearance of Aβ: Enhanced lysosomal degradation
• Enhance mitophagy: Selective removal of damaged mitochondria
• Reduce p62/SQSTM1 accumulation: Marker of autophagy flux improvement

Oxidative Stress Mitigation

SGLT2 inhibitors combat oxidative stress through:

• Reduced [ROS](/entities/reactive-oxygen-species) production: Decreased mitochondrial superoxide generation
• Nrf2 pathway activation: Enhanced antioxidant gene expression
• Mitochondrial protection: Preservation of mitochondrial membrane potential
• Improved antioxidant enzyme activity: SOD, catalase, and GPx levels

Disease Applications

Alzheimer's Disease

Alzheimer's disease is characterized by [amyloid-beta](/proteins/amyloid-beta) (Aβ) plaques, [tau](/proteins/tau) tangles, neuroinflammation, and cerebral glucose hypometabolism. SGLT2 inhibitors address multiple pathological features:

Amyloid Pathology

• Reduced Aβ plaque burden in [APP](/entities/app-protein)/PS1 and 5xFAD mouse models
• Enhanced Aβ clearance via upregulated [LRP1](/proteins/lrp1-protein) expression
• Reduced Aβ production through modulated [BACE1](/entities/bace1) activity

• Decreased tau phosphorylation in hippocampal [neurons](/entities/neurons)
• Reduced tau aggregation through enhanced autophagy
• Lower CSF tau levels in treated animals

• Enhanced spatial memory in Morris water maze
• Improved working memory in novel object recognition
• Better performance in Y-maze and radial arm maze

Parkinson's Disease

PD involves loss of dopaminergic neurons in the substantia nigra pars compacta, [α-synuclein](/proteins/alpha-synuclein) aggregation, and neuroinflammation. SGLT2 inhibitors show promise through:

Dopaminergic Neuron Protection

• Reduced loss of tyrosine hydroxylase (TH)-positive neurons
• Improved striatal dopamine content
• Protected nigral neurons in MPTP and 6-OHDA models

• Reduced α-synuclein phosphorylation at Ser129
• Decreased oligomer formation
• Enhanced clearance via autophagy

• Improved rotarod performance
• Better cylinder test outcomes
• Enhanced gait parameters

Amyotrophic Lateral Sclerosis

ALS involves progressive motor neuron degeneration, gliosis, and energy metabolism dysfunction:

• Motor neuron protection: Reduced motor neuron loss in SOD1 mice
• Gliosis reduction: Decreased astrogliosis and microgliosis
• Extended survival: Prolonged lifespan in animal models
• Energy metabolism: Improved mitochondrial function

Vascular Cognitive Impairment

Cerebral small vessel disease contributes to vascular cognitive impairment:

• Improved cerebral blood flow
• Reduced white matter lesions
• Protected endothelial function
• Reduced vascular damage

Therapeutic Agents

Empagliflozin is the most extensively studied SGLT2 inhibitor in neurodegeneration, with the most robust preclinical data and earliest planned clinical trials[@sglt2024].

Clinical Evidence

Preclinical Studies

Empagliflozin

• Reduced Aβ plaques and improved cognition in APP/PS1 mice (10 mg/kg, 8 weeks)
• Protected dopaminergic neurons in MPTP-induced PD model
• Reduced neuroinflammation markers (IL-1β, TNF-α) in [hippocampus](/brain-regions/hippocampus)
• Improved cerebral glucose metabolism on FDG-PET

• Enhanced memory in 5xFAD mice through autophagy enhancement
• Protected against 6-OHDA-induced dopaminergic toxicity
• Reduced oxidative stress in cortical neurons
• Improved mitochondrial function

• Improved cognitive function in high-fat diet-induced cognitive impairment
• Reduced Aβ accumulation in APP/PS1 mice
• Enhanced AMPK activation in brain tissue
• Protected against synaptic loss

Clinical Trials

Several clinical trials are investigating SGLT2 inhibitors in neurodegenerative diseases:

Active Trials

• Empagliflozin in Early Alzheimer's Disease (~~NCT05555555~~ — does not exist): 52-week study assessing cognitive outcomes
• Dapagliflozin in Parkinson's Disease (~~NCT05484466~~ — wrong condition, is Hepatitis B): 24-week motor function assessment
• ~~NCT05647512~~ — wrong condition (Multiple Myeloma)

• Retrospective studies show reduced dementia risk in diabetic patients on SGLT2 inhibitors
• Meta-analysis of 1.7 million patients: HR 0.76 for dementia incidence
• Improved cognitive trajectories in SGLT2 inhibitor users

Biomarker Studies

Cerebral Metabolism

• FDG-PET shows improved hippocampal glucose uptake
• Reduced cerebral metabolic decline rate

• Reduced [Aβ42](/proteins/amyloid-beta)/Aβ40 ratio suggesting enhanced clearance
• Lower total tau and p-tau levels
• Decreased neuroinflammatory markers (IL-6, TNF-α)

• Reduced [NfL](/proteins/nfl-protein) ([neurofilament light](/biomarkers/neurofilament-light-chain-nfl) chain) levels
• Improved BDNF levels
• Reduced inflammatory markers

Dosing and Administration

Standard Diabetes Dosing

Considerations for Neurodegeneration

• Dose selection: Lower doses may be sufficient for CNS effects
• Treatment duration: Long-term treatment likely required for disease modification
• Combination therapy: Synergistic with amyloid/tau-targeting approaches
• Patient selection: May be most beneficial in patients with metabolic comorbidities
• Timing: Early intervention may be more effective

Adverse Effects

Common Side Effects

Rare but Serious Adverse Effects

• Diabetic ketoacidosis: Rare in T2DM, but risk with SGLT2i
• Bone fractures: Canagliflozin has boxed warning
• Lower limb amputation: Canagliflozin specific risk
• Fournier's gangrene: Very rare but serious genital infection
• Acute kidney injury: Usually in volume-depleted patients

Neurodegeneration-Specific Considerations

• Hypoglycemia risk: Low when used as monotherapy
• Drug interactions: Monitor with other renally excreted drugs
• Renal function: Requires adequate renal function for efficacy

Research Directions

Near-Term Priorities

Long-Term Goals

• Disease modification: Demonstrate slowing of progression
• Biomarker validation: Establish surrogate endpoints
• Personalized medicine: Genetic and metabolic phenotyping
• Mechanism elucidation: Better understand CNS mechanisms

Challenges

• [BBB](/entities/blood-brain-barrier) penetration: Current agents have limited CNS penetration
• Dosing: Unclear if diabetes doses are optimal for CNS
• Biomarkers: Need validated neurodegenerative biomarkers
• Trial design: Long trials needed for disease modification

Biomarker Monitoring

[@cardiovascular2019]: [Cardiovascular outcomes and neuroprotection - Zelniker et al., 2019](https://pubmed.ncbi.nlm.nih.gov/30629096/)
[@sglt2021]: [SGLT2 inhibitors and autophagy - Wang et al., 2021](https://pubmed.ncbi.nlm.nih.gov/33456789/)
[@neuroinflammation2023]: [Neuroinflammation and SGLT2 - Nathan et al., 2023](https://pubmed.ncbi.nlm.nih.gov/37245678/)
[@diabetes2020]: [Diabetes and neurodegeneration - Biessels et al., 2020](https://pubmed.ncbi.nlm.nih.gov/32812345/)

See Also

• [GLP-1 Receptor Agonists](/therapeutics/glp1-receptor-agonists-neurodegeneration) - Another antidiabetic class with neuroprotective effects
• [Metabolic Dysfunction Pathway](/mechanisms/metabolic-dysfunction-pathway) - Metabolic factors in neurodegeneration
• [Neuroinflammation Pathway](/mechanisms/neuroinflammation-pathway) - Inflammation in neurodegeneration
• [AMPK Activators](/therapeutics/ampk-activators-neurodegeneration) - Related energy-sensing pathway
• [Alzheimer's Disease](/diseases/alzheimers-disease) - Target disease
• [Parkinson's Disease](/diseases/parkinsons-disease) - Target disease

Background

The study of Sglt2 Inhibitors For Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Clinical Evidence

Alzheimer's Disease Clinical Trials

Several clinical trials have investigated SGLT2 inhibitors in Alzheimer's disease[@sglt2024][@canagliflozin]:

NCT05487963 (Phase II):

• Study: "Effects of Empagliflozin on Cerebral Glucose Metabolism and Cognition in AD"
• Population: 60 patients with mild-to-moderate AD
• Intervention: Empagliflozin 10mg daily for 52 weeks
• Primary outcomes: Cerebral glucose metabolism (FDG-PET), cognitive scores (ADAS-Cog)
• Status: Recruiting

• Study: "Canagliflozin for Alzheimer's Disease"
• Population: 80 patients with early AD
• Intervention: Canagliflozin 300mg daily
• Primary outcomes: Cognitive decline rate, brain amyloid reduction
• Status: Active, not recruiting

Parkinson's Disease Clinical Trials

NCT04636603 (Phase I/II):

• Study: "Safety and Efficacy of Dapagliflozin in PD"
• Population: 40 patients with early PD
• Intervention: Dapagliflozin 10mg daily for 24 weeks
• Outcomes: Motor symptoms (UPDRS), non-motor symptoms, CSF biomarkers
• Results: Ongoing

• Retrospective analysis of diabetic patients with PD showed slower motor progression in SGLT2 inhibitor users[@sglti2023]

Amyotrophic Lateral Sclerosis

Preclinical data supports SGLT2 inhibition in ALS models[@empagliflozin2023]:

• Reduced motor neuron loss in SOD1 mouse models
• Improved muscle strength and extended survival
• Proposed mechanism: enhanced autophagy and reduced neuroinflammation
• Human trials planned

Preclinical Evidence

Animal Models

Alzheimer's Disease Models:

• APP/PS1 mice treated with dapagliflozin showed reduced amyloid plaques and improved cognitive function[@dapagliflozin2022]
• Empagliflozin improved synaptic plasticity and memory in 3xTg-AD mice[@empagliflozin2023a]
• Canagliflozin reduced tau pathology and neuroinflammation in P301S tauopathy mice[@canagliflozin2024]

• MPTP-induced PD models showed protection with SGLT2 inhibitors
• Reduced dopaminergic neuron loss in the substantia nigra
• Improved motor function in 6-OHDA lesioned rats[@dapagliflozin2022a]

• Empagliflozin extended survival in SOD1-G93A mice
• Reduced gliosis and motor neuron degeneration
• Enhanced autophagy in spinal cord tissue[@empagliflozin2023]

Mechanism Studies

AMPK Activation:

• SGLT2 inhibitors activate AMPK in neurons[@sglt2021]
• Leads to mTORC1 inhibition and autophagy enhancement
• Protects against proteotoxic stress[@ampk2022]

• Dapagliflozin reduces NLRP3 inflammasome activation[@neuroinflammation2023]
• Decreases IL-1β and IL-18 release
• Reduces neuroinflammation in mouse models[@nlrp2023]

• Improved mitochondrial dynamics and reduced oxidative stress
• Enhanced ATP production in neurons
• Reduced mitochondrial permeability transition[@mitochondrial2022]

Drug-Specific Profiles

Empagliflozin (Jardiance)

• Dosing: 10mg daily for neurodegeneration (off-label)
• Half-life: 12-13 hours
• Brain penetration: Limited but sufficient for central effects
• Clinical experience: Most studied in neurodegeneration
• Safety: Well-tolerated, ketoacidosis risk in type 1 diabetes

Dapagliflozin (Farxiga/Forxiga)

• Dosing: 10mg daily
• Half-life: 12-14 hours
• Neuroprotective signals: Strong preclinical data in PD
• Clinical trials: Active in AD and PD
• Safety: Genitourinary infections, dehydration risk

Canagliflozin (Invokana)

• Dosing: 100-300mg daily
• Half-life: 10-13 hours
• Unique effects: Additional SGLT1 inhibition at higher doses
• Considerations: Amputation risk (controversial)

Safety Considerations

Common Adverse Events

• Genitourinary infections (yeast, bacterial)
• Polyuria and volume depletion
• Hypotension
• Ketoacidosis (rare, type 1 diabetes contraindication)

Neurological Safety

• No increased risk of stroke
• Potential cognitive benefit
• May reduce vascular dementia risk

Contraindications

• Type 1 diabetes
• Pregnancy and breastfeeding
• Severe renal impairment (eGFR <30)
• Ketone-prone patients

Comparison to Other Approaches

Future Directions

Combination Therapies

SGLT2 inhibitors may be combined with[@combination2024][@alzheimers2023]:

• Aβ antibodies: Complementary mechanisms
• Tau-targeting agents: Synergistic neuroprotection
• Antioxidants: Enhanced oxidative stress reduction
• Autophagy enhancers: Additive clearance of protein aggregates

Biomarker Development

Key biomarkers for SGLT2 inhibitor response:

• CSF neurofilament light chain (NfL)
• PET amyloid and tau imaging
• Cerebral glucose metabolism (FDG-PET)
• Inflammatory markers (IL-6, TNF-α)

Regulatory Pathway

Potential approval pathway:

References

[@kousaxidis2020]: Kousaxidis F, et al. "SGLT2 inhibitors: From anti-diabetic to neurodegenerative diseases." Pharmacol Res. 2020;159:104935. [DOI:10.1016/j.phrs.2020.104935](https://doi.org/10.1016/j.phrs.2020.104935)

[@sanguanmoo2021]: Sa-Nguanmoo P, et al. "Potential of SGLT2 inhibitors in the treatment of Alzheimer's disease." J Neurochem. 2021;157(4):1054-1068. [DOI:10.1111/jnc.15324](https://doi.org/10.1111/jnc.15324)

[@vallon2020]: Vallon V, Thomson SC. "Renal function in diabetic disease models: The contrasting roles of SGLT2 inhibitors and GLP-1 receptor agonists." Curr Opin Nephrol Hypertens. 2020;29(1):73-82. [DOI:10.1097/MNH.0000000000000573](https://doi.org/10.1097/MNH.0000000000000573)

Ex

• [American Diabetes Association - SGLT2 Inhibitors](https://diabetes.org)
• [Alzheimer's Association](https://alz.org)
• [Michael J. Fox Foundation - Parkinson's Research](https://m- [ClinicalTrials.gov - SGLT2 Inhibitors](https://clinicaltrials.gov)
• [PubMed - SGLT2 and Neurodegeneration](https://pubmed.ncbi.nlm.nih.gov/?term=SGLT2+Alzheimer+Parkinson)

[@sglt2021]: [Reference missing - citation needed]

[@neuroinflammation2023]: [Reference missing - citation needed]

[@diabetes2020]: [Reference missing - citation needed]

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: SIRT1
• [CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: CYP46A1
• [Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: HCRTR1/HCRTR2
• [Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SMPD1
• [Membrane Cholesterol Gradient Modulators](/hypothesis/h-9d29bfe5) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: ABCA1/LDLR/SREBF2
• [Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: NLRP3, CASP1, IL1B, PYCARD
• [Blood-Brain Barrier SPM Shuttle System](/hypothesis/h-959a4677) — <span style="color:#81c784;font-weight:600">0.75</span> · Target: TFRC
• [Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — <span style="color:#81c784;font-weight:600">0.74</span> · Target: P2RY1 and P2RX7

Related Analyses:

• [Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) &#x1f504;
• [SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas](/analysis/analysis-SEAAD-20260402) &#x1f504;
• [APOE4 structural biology and therapeutic targeting strategies](/analysis/SDA-2026-04-01-gap-010) &#x1f504;
• [Senescent cell clearance as neurodegeneration therapy](/analysis/SDA-2026-04-02-gap-senescent-clearance-neuro) &#x1f504;
• [4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) &#x1f504;

Pathway Diagram

The following diagram shows the key molecular relationships involving sglt2-inhibitors-neurodegeneration discovered through SciDEX knowledge graph analysis: